Angiosarcomas and Taxanes
- 227 Downloads
Angiosarcomas (AS) are a heterogeneous group of rare and aggressive malignancies. The best treatment of localized AS includes wide resection following by adjuvant radiation therapy as possible. The current standard treatment of metastatic AS remains a doxorubicin-based regimen. This treatment provides a median progression-free survival and a median overall survival of about 4 and 8 months, respectively. Numerous case reports and retrospective studies have suggested that taxanes (paclitaxel or docetaxel) may provide some objective responses. The French Sarcoma Group has conducted a phase II clinical trial, which states the benefit of weekly paclitaxel in patients with unresectable or metastatic AS. After 2 cycles, the non-progression rate was 78% and complete histological responses were observed in 3 out of 30 cases. Further clinical studies are needed to confirm clinic impact of weekly paclitaxel on survival and to assess the role of taxanes in the multidisciplinary treatment of AS.
KeywordsPaclitaxel Docetaxel Clin Oncol Sorafenib Taxanes
Unable to display preview. Download preview PDF.
The authors specially thank the members of the “Bureau des Etudes Cliniques de la FNCLCC” (Marta JIMENEZ, Céline MAHIER, Jean GENEVE) and the members of the Groupe Sarcome Français (GSF/GETO) for their help in the management of the Angio-Tax Study.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: •Of importance ••Of major importance
- 5.•Fata F, O’Reilly E, Ilson D, Pfister D, et al.: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999, 86:2034–2037Google Scholar
This is the first “large” retrospective case reports which suggest a potential efficacy of paclitaxel in angiosarcomas of scalp and face. The response rate was 8/9 patients.
- 17.Tomascello L, Gardin G, Boccardo F: Secondary breast angiosarcoma: lethal response to antiangiogenic therapy with paclitaxel chemotherapy. A case report. Anticancer Res 2006, 26:4775–4777Google Scholar
- 20.Veliz M, Chang V, Kasimis B, Choe JK: Durable response of angiosarcoma of the face and scalp to docetaxel. Clin Oncol (R Coll Radiol) 2007, 19:210Google Scholar
- 24.Schlemmer M, Reichardt P, et al.: Paclitaxel in patients (pts) with advanced angiosarcomas (Abstract 10033). J Clin Oncol 2007, 25:553SGoogle Scholar
- 25.••Penel N, Bui Nguyen B, Bay JO, et al.: Weekly paclitaxel in metastatic angiosarcoma. A FNCLCC French Sarcoma Group (GSF-GETO) phase II trial (Abstract 10002). J Clin Oncol 2007, 25:545sGoogle Scholar
This is the first clinical trial evaluating a chemotherapy regimen in patients with angiosarcomas. This phase II trial clearly establishes a non-progression of 78% after 2 cycles and an overall survival of 7.6 months. Two histological complete responses were observed.
- 30.D’Adamo DR, Keohan M, Schuetze S, et al.: Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060). (Abstract 10001). J Clin Oncol 2007, 25:545sGoogle Scholar
- 35.•Pasquier E, Carre M, Pourroy B, et al.: Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptosis signaling pathway. Mol Cancer Ther 2004, 3:1301–1310Google Scholar
This preclinical study explores the anti-angiogenic activity of low dose of paclitaxel. These findings suggest an induction of apoptosis via mitochondrial signaling pathway.
- 38.Verweij J, Lee SM, Ruka W, et al.: Randomized phase II study of docetaxel versus doxorubicin in first-line and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000, 18:2081–2086PubMedGoogle Scholar
- 39.Enzinger FM, Weiss SW. Malignant vascular tumors. In Soft Tissue Tumors, Third Edition. Edited by Enzinger FM, Weiss SW. Saint-Louis Missouri: Mosby; 1995:641–678Google Scholar